Leqembi Pen (Subcutaneous Formulation Of Leqembi) Now Available In Japan For Patients With Early Alzheimer's Disease
BRIEF-Eisai Co., Ltd.- Leqembi Pen (Subcutaneous Formulation Of Leqembi) Now Available In Japan For Patients With Early Alzheimer's Disease Nov 13 (Reuters) - Eisai Co., Ltd. 4523.T:
EISAI CO., LTD.: LEQEMBI PEN (SUBCUTANEOUS FORMULATION OF LEQEMBI) NOW AVAILABLE IN JAPAN FOR PATIENTS WITH EARLY ALZHEIMER'S DISEASE
Source text: ID:nTSwl8d03b
Further company coverage: 4523.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Eisai
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Now Available In Japan For Patients With Early Alzheimer's Disease
Table: Eisai -6-MTH group results (IFRS)
Biogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs